CTLA4 and neoplasm: Ipilimumab is a representative of CTLA‐4 inhibitors that activate T cell anti‐tumor responses by removing tumor‐induced immunosuppression.2 However, with the vigorous development of therapeutic drugs at tumor immune checkpoints, the side effects of these new drugs began to surface, and the clinical safety of these drugs was a concern.